Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.

Digestive diseases and sciences - 1 Dec 2021

Harris Dana M, Stancampiano Fernando F, Burton M Caroline, Moyer Ann M, Schuh Michael J, Valery Jose R, Bi Yan

Abstract excerpt

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical...

Topics

Join the communities discussing this publication.

Clinical Decision-Making
Cytochrome P-450 CYP2C19
Decision Support Techniques
Pharmacogenetics
Pharmacogenomic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pharmacogenomic Variants

Proton Pump Inhibitors

Source

Identifiers

PMID: 33475867
DOI: 10.1007/s10620-020-06814-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.PMID 33475867Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Semantic proximity Read ↗

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemSemantic proximity Read ↗

New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Semantic proximity Read ↗

Pharmacogenomics in gastrointestinal disorders.Semantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Pharmacogenetics: An Important Part of Drug Development with A Focus on Its ApplicationSemantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.